Karyopharm Therapeutics (KPTI) Stock: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$0.48
-0.07 (-11.92%)
âŧ
5d:
+23.3%
30d:
-72.2%
90d:
-93.22%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 02, 2026
9d
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KPTI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KPTI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $0.48, which is considered slightly low relative to its 30-day fair value range of $0.45 to $1.61.
Technical Outlook: Technically, KPTI is in a strong downtrend. Immediate support is located at $0.31, while resistance sits at $0.63. Short-term momentum is weak, with the stock down 11.9% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.25 (+1227.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KPTI is in a strong downtrend. Immediate support is located at $0.31, while resistance sits at $0.63. Short-term momentum is weak, with the stock down 11.9% recently.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.25 (+1227.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.45 -
$1.61
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-11.9%)
- BULLISH: Trading 1227.6% below Wall St target ($7.25)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.45 -
$1.61
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.31
Resistance Level
$0.63
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.19
Wall Street Target
$7.25
(+1227.6%)
Revenue Growth (YoY)
-11.9%
Profit Margin
-153.3%
Share & Embed Analysis
Last updated: October 23, 2026 10:50 AM ET
Data refreshes hourly during market hours. Next update: 11:50 AM
Data refreshes hourly during market hours. Next update: 11:50 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |
|
CGON
CG Oncology, Inc. CommonâĻ |
STRONG BUY
15 analysts |
$91 | 64 BUY |
